Nasonex, Rozerem ads most recalled of 2007

Share this article:
Nasonex ad tops in consumer recall
Nasonex ad tops in consumer recall

DTC TV prescription drug ads featuring an animated bee and a talking beaver were most recalled by consumers during 2007, according to ad performance tracking firm IAG Research.

A 30-second spot featuring Schering-Plough's Nasonex bee was the most recalled broadcast and cable TV ad, followed by a 60-second spot for Takeda's Rozerem featuring the tagline “Your Dreams Miss You.”

Ads for Merck/Schering/Plough's Vytorin and Pfizer's Lipitor featuring Dr. Robert Jarvik followed close behind in terms of consumer ad recall. (See data below).

Most recalled new prescription drug/vaccine ads -- (based on new ads launched in calendar 2007 - 1.1.07 through 12.31.07)

1. Nasonex,Schering-Plough- Animated bee talks about prevention of allergy symptoms, 30- second spot

2. Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at bus stop; "Your Dreams Miss You", 60-second spot

3.Vytorin, Merck/Schering-Plough- Plates of food next to shots of relatives; tuna and peas, Grandma Louise, 60-second spot

4.Lipitor, Pfizer- Dr. Robert Jarvik in white lab coat discusses heart disease, 60-second spot

5.(Tie) Chantix Pfizer- Tortoise and hare, 60-second spot
Vytorin, Merck/Schering-Plough- Plates of food next to shots of realtives; Grandpa Bo, bowtie pasta, 60-second spot

6.(Tie) Lunesta, Sepracor- Luna moth flies into bedrooms, 60-second spot
Cialis Eli Lilly- Couples in various romantic places, 60-second spot

7.(Tie)Gardasil, Merck- Various young women (cowgirl, colorguard, gymnast) Tagline: "One Less," 60-second spot
Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at office; "Your Dreams Miss You," 60-second spot

-courtesy IAG Research

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.